RT @WNicholsonPrice: One view by an ex-Federal Circuit judge: patentability limits led to fewer COVID-19 diagnostic tests. (C. Deb, @osman…
One view by an ex-Federal Circuit judge: patentability limits led to fewer COVID-19 diagnostic tests. (C. Deb, @osmanmoneer, & I argued otherwise, that patents are unlikely to help in this space, in @J_Law_Biosci: https://t.co/8QESgy9hzf)
RT @WNicholsonPrice: Why were single-sourced diagnostic tests so problematic early in the pandemic, and what's patent law got to do with it…
RT @WNicholsonPrice: Why were single-sourced diagnostic tests so problematic early in the pandemic, and what's patent law got to do with it…
RT @WNicholsonPrice: Why were single-sourced diagnostic tests so problematic early in the pandemic, and what's patent law got to do with it…
Why were single-sourced diagnostic tests so problematic early in the pandemic, and what's patent law got to do with it? @chaarudeb, @osmanmoneer, & I have a piece out in @J_Law_Biosci today (preprint up before, but finally up for real today)! Open acce
RT @SolomonCtrYLS: Solomon Center Student Fellows Chaaru Deb '21 and @osmanmoneer wrote a piece on innovation policy for diagnostic testing…
Solomon Center Student Fellows Chaaru Deb '21 and @osmanmoneer wrote a piece on innovation policy for diagnostic testing in @J_Law_Biosci. Check it out! https://t.co/xt2UxTxILa
RT @osmanmoneer: As we recently saw with the United States's initial response to Covid-19, single-sourced diagnostic tests hamper clinical…
RT @osmanmoneer: As we recently saw with the United States's initial response to Covid-19, single-sourced diagnostic tests hamper clinical…
RT @osmanmoneer: As we recently saw with the United States's initial response to Covid-19, single-sourced diagnostic tests hamper clinical…
RT @WNicholsonPrice: Why was the US' early COVID-19 testing rollout so botched, and what can we learn about innovation policy more generall…
RT @osmanmoneer: As we recently saw with the United States's initial response to Covid-19, single-sourced diagnostic tests hamper clinical…
RT @HankGreelyLSJU: /3 Chaarushena Deb, Osman Moneer, W Nicholson Price, II, Covid-19, Single-Sourced Diagnostic Tests, and Innovation Pol…
RT @osmanmoneer: As we recently saw with the United States's initial response to Covid-19, single-sourced diagnostic tests hamper clinical…
RT @osmanmoneer: As we recently saw with the United States's initial response to Covid-19, single-sourced diagnostic tests hamper clinical…
could not be more proud of @osmanmoneer for this thoughtful and timely paper!
RT @WNicholsonPrice: Why was the US' early COVID-19 testing rollout so botched, and what can we learn about innovation policy more generall…
As we recently saw with the United States's initial response to Covid-19, single-sourced diagnostic tests hamper clinical practice. For more on innovation policy for diagnostics, check out my paper with @WNicholsonPrice and Chaaru Deb in @J_Law_Biosci!
RT @WNicholsonPrice: Why was the US' early COVID-19 testing rollout so botched, and what can we learn about innovation policy more generall…
RT @WNicholsonPrice: Why was the US' early COVID-19 testing rollout so botched, and what can we learn about innovation policy more generall…
Why was the US' early COVID-19 testing rollout so botched, and what can we learn about innovation policy more generally from that failure? New piece out with Chaaru Deb (@YaleLawSch) & @osmanmoneer (@YaleMed) in @J_Law_Biosci: https://t.co/1kWgAoVKJz
/3 Chaarushena Deb, Osman Moneer, W Nicholson Price, II, Covid-19, Single-Sourced Diagnostic Tests, and Innovation Policy, https://t.co/uGbIpuRGw9 The complete table of contents can be found at https://t.co/3ChuYeBDzp